UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported) March
30, 2006
Interpharm
Holdings, Inc.
(Exact
name of Registrant as specified in charter)
Delaware
|
0-22710
|
13-3673965
|
(State
or other jurisdic-
|
(Commission
|
(IRS
Employer
|
tion
of incorporation)
|
File
Number)
|
Identification
No.)
|
|
|
|
|
|
|
75
Adams Avenue, Hauppauge, New York
|
11725
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (631)
952-0214
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers
Effective
immediately, Interpharm Holdings, Inc. has appointed Mr. Kenneth Cappel as
its
General Counsel.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
INTERPHARM HOLDINGS,
INC. |
|
|
|
March
30, 2006
|
|
By:
/s/ George
Aronson
|
|
|
George
Aronson
|
|
|
Chief
Financial Officer
|